<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327638</url>
  </required_header>
  <id_info>
    <org_study_id>0663-159</org_study_id>
    <secondary_id>EP07013.013.11.082</secondary_id>
    <nct_id>NCT01327638</nct_id>
  </id_info>
  <brief_title>Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)</brief_title>
  <official_title>Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is intended to provide additional post-marketing safety data regarding the use of
      etoricoxib for the indication of ankylosing spondylitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific project objectives are to:

      1) Describe the characteristics of Swedish patients with inflammatory SpA/AS ; 2) Describe
      the use of etoricoxib and other cyclooxygenase-2 (COX-2 inhibitors)/non-selective
      nonsteroidal anti-inflammatory drugs (nsNSAIDs) in Swedish patients with SpA/AS; and 3)
      Estimate and compare the rates of clinical outcomes of special interest (gastrointestinal,
      renovascular, cardiovascular and cerebrovascular) with use of etoricoxib and other COX-2
      inhibitors/nsNSAIDs in Swedish patients with SpA/AS. Comparisons of clinical outcomes among
      the drugs of interest will be made by descriptive comparison of the point estimates for the
      incidence rates and their associated 95% confidence intervals (CIs), using both clinical and
      epidemiological judgment and in light of the limitations of this observational study. No
      formal statistical significance testing will be performed for purposes of such comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2011</start_date>
  <completion_date type="Actual">December 6, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Characteristics of inflammatory SPA/AS</measure>
    <time_frame>Over a 12 year period (2001-2013)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who used etoricoxib</measure>
    <time_frame>Up to 7 1/2 years (Q3 2005 - 2013)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who used other COX-2 inhibitors</measure>
    <time_frame>Up to 7 1/2 years (Q3 2005 - 2013)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who used nsNSAIDs</measure>
    <time_frame>Up to 7 1/2 years (Q3 2005 - 2013)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinical outcomes of special interest</measure>
    <time_frame>Up to 7 1/2 years (Q3 2005 - 2013)</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">21108</enrollment>
  <condition>Spondylarthropathies; Spondylitis, Ankylosing</condition>
  <arm_group>
    <arm_group_label>Patients with SpA/AS and etoricoxib treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with SpA/AS and other COX-2 inhibitor treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with SpA/AS and nsNSAIDs treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Patients with SpA/AS who took etoricoxib</description>
    <arm_group_label>Patients with SpA/AS and etoricoxib treatment</arm_group_label>
    <other_name>MK-0663; Arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other COX-2 inhibitor</intervention_name>
    <description>Patients with SpA/AS who took other COX-2 inhibitors</description>
    <arm_group_label>Patients with SpA/AS and other COX-2 inhibitor treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nsNSAIDs</intervention_name>
    <description>Patients with SpA/AS who took nsNSAIDs</description>
    <arm_group_label>Patients with SpA/AS and nsNSAIDs treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Out-patients in Sweden with SpA/AS who took etoricoxib, other COX-2 inhibitors, or nsNSAIDs
        from 2001-2010.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant attended an out-patient clinic 2001-2010.

          -  Participant is registered with an International Classification of diseases (ICD,
             Version 10)-code corresponding to SpA/AS and AS.

        Exclusion Criteria:

        Not applicable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.encepp.eu/encepp/viewResource.htm?id=27099</url>
    <description>EU PAS Register (EUPAS19202)</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>December 24, 2018</last_update_submitted>
  <last_update_submitted_qc>December 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthropathies</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

